Účinnost Equoralu v profylaktické imunosupresi u nemocných po transplantaci ledviny

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F07%3A00004300" target="_blank" >RIV/61989592:15110/07:00004300 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/61988987:17110/07:A1100UBC

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Efficacy of Equoral in prophylactic immunosuppression after de novo kidney transplantation

Popis výsledku v původním jazyce

Cyclosporin A is a well-known calcineurin ihibitor that has been used for prophylactic immunosuppression after organ transplantation. The aim of this study was to evaluate the efficacy and safety of a new generic cyclosporin formulation, Equoral (Teva Pharmaceuticals), in the treatment of de novo renal transplant. Twenty cadaveric-donor renal transplant recipients between 23 and 71 years of age at the time of transplantation (mean age 52?12,5 years) were followed for 12 months to determine if the graftsfunctioned and if there were rejection attacks and side effects. In addition to cyclosporin, all patients received mycophenolate mofetil (CellCept) and prednisone (Prednison). Mean serum creatinine level decreased significantly after transplantation. In6 of the 20 patients observed, 7 biopsies showed acute rejection episodes (35%). Over the 12 month post-transplant period, all patients showed stable graft function, with a mean serum creatinine level of 202,1?130,9 umol/l. Patient and r

Název v anglickém jazyce

Efficacy of Equoral in prophylactic immunosuppression after de novo kidney transplantation

Popis výsledku anglicky

Cyclosporin A is a well-known calcineurin ihibitor that has been used for prophylactic immunosuppression after organ transplantation. The aim of this study was to evaluate the efficacy and safety of a new generic cyclosporin formulation, Equoral (Teva Pharmaceuticals), in the treatment of de novo renal transplant. Twenty cadaveric-donor renal transplant recipients between 23 and 71 years of age at the time of transplantation (mean age 52?12,5 years) were followed for 12 months to determine if the graftsfunctioned and if there were rejection attacks and side effects. In addition to cyclosporin, all patients received mycophenolate mofetil (CellCept) and prednisone (Prednison). Mean serum creatinine level decreased significantly after transplantation. In6 of the 20 patients observed, 7 biopsies showed acute rejection episodes (35%). Over the 12 month post-transplant period, all patients showed stable graft function, with a mean serum creatinine level of 202,1?130,9 umol/l. Patient and r

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FE - Ostatní obory vnitřního lékařství

OECD FORD obor

—

Projekt

—

Návaznosti

S - Specificky vyzkum na vysokych skolach

Rok uplatnění

2007

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Dialysis and Transplantation

ISSN

0090-2934

e-ISSN

—

Svazek periodika

36

Číslo periodika v rámci svazku

11

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

6

Strana od-do

602-607

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—